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LUNG FUNCTION DETERMINANTS AND MORTALITY OF CHILDREN AND ADOLESCENTS WITH 
CYSTIC FIBROSIS IN SOUTH AFRICA 2007-2016 
 
Authors: Natalie Vandenbroucke; Marco Zampoli; Brenda Morrow 
 
Objectives: Cystic fibrosis (CF) is one of the commonest inherited disorders in South Africa, 
affecting all population groups. Progressive pulmonary disease with declining forced expiratory 
volume in one second (FEV1) is the main predictor of morbidity and mortality in individuals with 
CF. This study aimed to describe the change in lung function, nutritional status and mortality of 
children and adolescents with CF, attending the Red Cross War Memorial Children’s Hospital 
(RCWMCH) CF Clinic and to identify factors associated with poor pulmonary function outcomes 
and mortality. 
 
Methods: A retrospective study was conducted of the clinical records and annual pulmonary 
function tests, with matched body mass index (BMI), of children between 5 and 18 completed 
years of age attending the RCWMCH CF clinic in Cape Town, South Africa, between January 2007 
and December 2016.  
 
Results: A total of 143 study participants (51.4% male; median age at diagnosis 5.5 months) were 
included. Population mean FEV1 and body mass index (BMI) Z scores improved from -2.5  1.70 
to -1.9  1.70 (p = 0.1) and from -0.7  1.2 to -0.4  1.2 (p = 0.3) respectively from 2007 to 2016. 
FEV1 Z score declined by an average of 0.17 per year of age and this was mirrored by an average 
decline in BMI Z scores of 0.07 for each year of advancing age. FEV1 decline was greater in 
patients who died compared to those who survived (p = 0.03). Of the factors postulated to 
influence lung function decline, there was no significant correlation between FEV1 at any age and 
age of diagnosis, sex, ethnicity, genotype, geographical location, pancreatic status, or Methicillin-
resistant S. aureus or Aspergillus spp. infection. Participants who were ever infected or colonised 
with P. Aeruginosa had consistently lower FEV1, however this difference only became significant 
at certain ages. On multiple stepwise regression analysis, only FEV1 at age 6 was found to be a 
significant independent predictor of mortality (adjusted odds ratio (95% CI) 0.5 (0.3 – 0.8); p = 
0.005).  
 
Conclusion: Pulmonary function of children with cystic fibrosis improved non-significantly over 
the 10-year study period. FEV1 at age 6 was identified as an independent predictor for CF-related 
mortality. Early diagnosis and measurement of pulmonary function in young children with CF is 
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
1.1.BACKGROUND: 
Cystic fibrosis (CF) is a genetic disorder of autosomal recessive inheritance which is caused by 
mutations in the gene encoding for the cystic fibrosis transmembrane conductance regulator 
(CFTR)(1). It is a chronic progressive condition involving multiple organ systems which 
ultimately compromises their function (2). CF is one of the commonest inherited diseases in 
South Africa, affecting all population groups (3). Progressive pulmonary disease is the main 
predictor of morbidity and mortality in individuals with CF. CF lung disease is characterized by 
chronic endobronchial infection and inflammation which eventually causes airway 
obstruction and damage, ultimately leading to irreversible obstructive airway disease and 
respiratory failure (4, 5).  
 
In addition to structural changes in the lungs, the progression of CF lung disease is 
predominantly described as deterioration in lung function over time (1) which has previously 
been noted to be predictable in developed countries (6).  
 
Pulmonary function tests, including spirometry and lung clearance indices, serve as an 
objective and practical way to assess severity and survey the evolution of lung disease (6). 
The measurement of forced expiratory volume in 1 second (FEV1) by spirometry is particularly 
useful, as this measure is widely available even in resource-limited settings. A decline in FEV1 
has been shown to be a predictor of hospitalization and is strongly associated with mortality. 
Thus, FEV1 can be used as an indicator for clinicians to change or intensify therapeutic 
regimens when treating patients with CF (2, 6). 




Multiple factors associated with FEV1decline have been identified through studies conducted 
in developed countries. These include, amongst others: young age, female gender, high lung 
function, CFTR genotype, pancreatic insufficiency, diabetes mellitus, poor nutritional status, 
and infection with Pseudomonas aeruginosa and Burkholderia cepacia (7).  
 
Children with CF in a resource-constrained country like South Africa however, face other 
hurdles such as poorer access to healthcare, and exposures such as the use of biomass fuels 
and an increased prevalence of different respiratory infections, including pulmonary 
tuberculosis (6). In many cases, FEV1 only becomes abnormal in the later stages of CF (2).  
By early identification of factors that predict lung function deterioration, it is hoped that we 
might slow the progression of lung disease in patients with CF, and by doing so, improve 
survival and healthy longevity in people with CF. 
 
However, studies examining decline in FEV1, and factors contributing to this decline in 
developing countries, are lacking. Currently studies assessing pulmonary function in patients 
with CF in South Africa have only been conducted in two centres, namely Red Cross War 
Memorial Children’s Hospital (RCWMH) in Cape Town, and Steve Biko Academic Hospital in 
Pretoria (3, 6, 8).  
 
Morrow et al documented a significant improvement in lung function of children with CF 
managed at RCWMH in the Western Cape province of South Africa over the period from 1999 
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to 2006. This is very encouraging, however the observed improvement was noted to occur at 
a time where medical care for patients with CF was rapidly evolving (6) and it is unclear 
whether these improvements have been sustained in the subsequent decade. One of the 
main objectives of CF management is to preserve lung health and slow the progression of lung 
disease, and this medical management is guided by research (1).  
 
1.2. LITERATURE REVIEW: 
1.2.1 AIMS AND OBJECTIVES: 
The aims and objectives of this study are to: 
1. Describe the modifiable and non-modifiable predictors of pulmonary function decline, 
in children with CF. 
2. Identify areas where further research may be beneficial. 
1.2.2 SEARCH METHODS: 
An online search using the Pubmed Database was conducted. The following keywords were 
used to undertake 12 searches of the database: 
Search #1: Cystic fibrosis AND Pulmonary function tests AND South Africa 
Search #2: Cystic fibrosis AND Pulmonary function AND children AND ethnicity 
Search #3: Cystic fibrosis AND Pulmonary function AND children AND socio-economic status 
Search #4: Cystic fibrosis AND Pulmonary function AND children AND outcomes AND age at 
diagnosis 
Search #5: Cystic fibrosis AND Pulmonary function AND children AND pancreatic insufficiency 
Search #6: Cystic fibrosis AND Pulmonary function AND children and MRSA 
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Search #7: Cystic fibrosis AND Pulmonary function AND children AND Methicillin-Resistant 
Staphylococcus Aureus 
Search #8: Cystic fibrosis AND Pulmonary function AND children AND Aspergillus Fumigatus 
Search #9: Cystic fibrosis AND Pulmonary function AND children AND Non-tuberculous 
Mycobacterium 
Search #10: Cystic fibrosis AND Pulmonary function AND children AND Pseudomonas 
Search #11: Cystic fibrosis AND Pulmonary Function AND children and BMI and Nutrition 
Search #12: Cystic fibrosis AND Pulmonary Function AND children AND gender and mortality 
Filters used were: Humans; abstract; free full text.  
The most recent search was conducted on 09 March 2019. Titles and abstracts were reviewed 
to identify relevant publications. References of these publications were then explored, and 
relevant articles were extracted.  
 
1.2.3 INCLUSION CRITERIA 
All types of study design were considered for inclusion, however only those published in 
English were used. Studies involving both children up to 18 years old and adults were included 
if these categories were individually analysed and the study was deemed relevant. No 
limitation was placed on date of study, however more recent studies conducted in the last 
10-15 years were prioritised.  
 
1.2.4 EXCLUSION CRITERIA 
Studies exclusively involving adults. 




1.3 SEARCH RESULTS 
The initial search revealed 873 studies, of which 36 met inclusion criteria.  
 




The relationship between gender and the decline in pulmonary function demonstrated by a 
decrease in FEV1, is still unclear with conflicting results from different studies (1).  Previous 
studies have reported a “gender gap” (1), suggesting that female sex is a risk factor for severe 
lung disease (9). A systematic review by Harun et al. found that adult females had a steeper 
decline in FEV1 % predicted when compared to males (1). It has been postulated that estrogen 
upregulates airway mucus production, thereby impairing mucociliary clearance and resulting 
in poorer lung function in females (10). Other studies that have shown a steeper decline in 
FEV1 in females than males have attributed this to different degrees of physical activity (6). A 
study by Cory et al found that male patients had a slower decline in FEV1 and increased 
survival which in turn equates to milder disease in males than in females. (11)Similar 
pulmonary function for males and females at baseline was noted by Harun et al (1). In a South 
African study by Morrow et al, no difference in FEV 1 decline between male and female 
participants could be demonstrated (6). One retrospective observational study by Cogen et al 
which involved participants in the Early Pseudomonas Infection Control (EPIC) Observational 
Study showed that females had a steeper rate of decline in pulmonary function than males, 
although the participants in this study had relatively mild disease. Of note is that this study 
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also showed that this steeper rate of decline was not due to earlier infection of female CF 
patients with Pseudomonas aeruginosa (PA) (10).  
GENOTYPE: 
It has proved very difficult to make a definitive genotype-phenotype correlation in patients 
with CF, specifically because the presentation, clinical evolution and prognosis for these 
patients is so varied. Delta F508 is the most common CF genetic mutation in Caucasian and 
mixed-race populations in South Africa, and it is associated with earlier presentation, 
pancreatic insufficiency and more severe lung disease (12). This was demonstrated in a Danish 
study by Johansen where significantly more patients homozygous for Delta F508 were 
symptomatic by 6 months of age, diagnosed at a younger age, required more pancreatic 
enzyme replacement therapy, and had poorer pulmonary function (13). A systematic review 
by Harun et al found that patients homozygous for the F508 mutation have a more rapid 
decline in pulmonary function compared to patients with other mutation types (1). This was 
corroborated in studies by Morrow et al and Corey et al which showed that Delta F508 
homozygous CF patients had a much greater rate of decline in pulmonary function (6, 11). 
Morrow et al however also showed that baseline pulmonary function at 6 years of age was 
significantly lower in CF patients who were Delta F508 heterozygous, but suggested that 
pulmonary disease in this group of patients may thereafter become more stable than Delta F 
508 homozygous counterparts. The relationship between Delta F 508 mutation types and 
severity of lung disease still needs to be studied further in  South Africa (6). Several studies 
have shown an association between CFTR mutation and pancreatic insufficiency (12), and 
thus most studies examining genotype-phenotype correlation were confounded by 
pancreatic status, specifically in the F508 deletion group (1). It is therefore still unclear as to 
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whether rate of FEV1 decline % predicted is influenced by pancreatic function or genotype 
(1).    
 
PANCREATIC INSUFFICIENCY 
Pancreatic insufficiency is a well-recognised gastrointestinal complication in patients with CF 
(1). Pancreatic status is associated with CFTR genotype, and is thus an intrinsic factor that 
cannot be treated, however new therapies are under investigation which are aimed at 
converting a “severe” CFTR mutation into a “mild” mutation where the CFTR is partially 
functional (14). Therefore, pancreatic insufficiency may, in future, rather become a modifiable 
factor. Corey et al’s 1997 study showed that patients with pancreatic sufficiency had a slower 
rate of decline of FEV1 (11). This finding was corroborated in a systematic review by Harun et 
al which indicated that pancreatic insufficiency was associated with a steeper decline in FEV1 
% predicted (1).  Thus, studies that assess pulmonary function in patients with CF must take 
into account patients’ pancreatic status which may vary between groups (14). It is well 
recognised that patients with pancreatic sufficiency have better nutritional status (14), 
whereas patients with pancreatic insufficiency have poorer nutritional status which causes 
poorer pulmonary function and lung growth, and ultimately faster decline in pulmonary 
function (1). An important study by Kerem et al controlled for other modifiable factors known 
to affect pulmonary function in patients with CF, namely nutrition, infection with 
Pseudomonas aeruginosa, and CF related diabetes. By doing so, study researchers were able 
to prove that patients with pancreatic sufficiency have better pulmonary function 
independent of these modifiable factors (14). Unfortunately, there is a paucity of South 
African studies examining the relationship between pancreatic status and pulmonary function 
in patients with CF.  





AGE AT DIAGNOSIS: 
 
With the advent of newborn screening for CF, much debate regarding the benefits of early vs 
late diagnosis of CF, in terms of pulmonary function and outcome, has fuelled multiple studies 
looking at this topic, however, results are inconclusive. Morrow et al suggested that there 
may be crucial events that occur at a very young age which may dictate the severity of a 
patients CF pulmonary disease. Therefore, early diagnosis, improved methods of monitoring 
in young patients, and optimal timeous management, is essential to slow the rate of decline 
of lung function and thereby increase survival of patients with CF (6). Several international 
studies have shown no difference in the severity of lung disease between patients diagnosed 
with CF through newborn screening versus patients diagnosed later with symptoms of CF (9, 
15, 16). Sanders et al noted that better outcomes in CF are not guaranteed by newborn 
screening, however early diagnosis through newborn screening does afford the opportunity 
for better care resulting in improved nutrition and cognitive function in patients with CF (9). 
A 10 year French retrospective study by Siret et al, despite finding no difference in lung 
function, did find that children with CF diagnosed through newborn screening experienced 
fewer delays in initiating pancreatic enzyme supplementation, fewer hospitalizations and had 
better Z scores for weight and height than non-screened patients with CF (15). Two 
international studies demonstrated improved lung function in patients diagnosed with CF at 
an earlier age. A retrospective cohort study by Slieker et al found that an early diagnosis of CF 
was associated with better pulmonary function after two decades of life despite the fact that 
younger siblings seemed to be colonised with Pseudomonas at an early age (17). In an 
Australian retrospective review of patients with late diagnosis of CF, Coffey et al found that 
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patients with late diagnosis CF had more respiratory manifestations at the time of diagnosis 
which equated to worse health, as well as poorer growth and worse pulmonary health later 
on (18).  
A local study by Morrow et al found that patients with CF diagnosed after 5 years of age had 
FEV1 values consistent with moderately severe lung disease (averaging <55% predicted) 
compared to those diagnosed earlier who had FEV1 values consistent with mild lung disease 
(averaging >75% predicted). Results of this study suggest that suboptimal management in 
early life potentially impacts negatively on early lung function (6).  
 
SOCIOECONOMIC STATUS (SES): 
A strong association between SES and PFT has been demonstrated in international studies 
from the United Kingdom and the USA, and the reasons for this association are multifactorial 
(19). Connections have been drawn between poorer SES and worse clinical outcomes in 
patients with CF (20). This may be partly explained by the fact that FEV1 has been shown to 
be affected by SES in cross sectional analyses (10), and we know that FEV1 not only accurately 
demonstrates the progression of CF lung disease, but can be used to predict mortality too (6). 
Low SES is associated with poorer nutrition and lung function as well as a significant two to 
three times higher mortality rate (19).  
CF affects all South African population groups and is an important, progressive chronic disease 
in our country (6). In a developing country such as South Africa, children with CF face 
additional exposures such as biomass fuel exposure and increased community prevalence of 
respiratory infections, and may have poorer access to health care than children living in 
developed countries, all of which may impact on pulmonary function (6) . In two South African 
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studies by Morrow et al, ethnic group was used as a substitute for SES, as black Africans and 
people of mixed ancestry tend to reside in in worse socio-economic environments than white 
South Africans, owing to historical inequities. Patients with CF that are of mixed ancestry have 
been found to have overall higher mortality (6). Interestingly, both studies suggest that 
poorer patients are becoming less disadvantaged, as no difference in pulmonary function or 
prognosis in different ethnic groups could be demonstrated (3, 6). 
Patients with CF should adhere to somewhat complex treatment regimens in order to slow 
disease progression and reduce the chance of early mortality. These regimens often include 
inhaled therapies, such as bronchodilators and mucolytics, antibiotics, as well as airway 
clearance therapy (ACT). The impact of SES on adherence has been clearly demonstrated in 
many chronic diseases, but less so in CF. Most studies have investigated adherence to specific 
medication regimens in CF patients rather than ACT, which is the most time-consuming aspect 
of the CF treatment regimen (21). A study conducted at the Children’s of Alabama CF centre, 
which used Cockerham’s Lifestyle theory which maintains that health behaviours are shaped 
by socio-economic conditions, demonstrated that a SES-adherence association does exist in 
CF, specifically for ACT. This study echoed previous study findings of an association between 
SES and pulmonary health by illustrating that better respiratory outcomes were associated 
with college education, income and the number of adults in each household. Analyses showed 
that college education was associated with medium adherence and medium lung function; 
high income is associated with high adherence, and that for every additional adult in a 
household, the likelihood of medium adherence is doubled, while the likelihood of high lung 
function is quadrupled. Therefore, the risk of worse respiratory outcomes due to poor 
adherence is higher in single adult households (21).  
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Pulmonary function in healthy children has been shown to be adversely affected by exposure 
to second-hand smoke. However, previous studies which aimed to demonstrate the 
association between second- hand smoke exposure and poorer outcomes in children with CF 
have been inconsistent, which is thought to be largely due to the differences in power of the 
various studies to determine the negative effects of second-hand smoke exposure. A powerful 
study conducted in the US, using data collected by the US Cystic Fibrosis Twin and Sibling 
study and the Cystic Fibrosis Foundation Data registry, confirmed that poorer lung function 
was associated with a higher prevalence of environmental tobacco smoke exposure in 
patients with CF, particularly in those with low SES. This study also demonstrated that 
adjustment for second-hand smoke exposure significantly altered the relationship between 
SES and CF outcomes, indicating that the relationship between low SES and lower pulmonary 
function is largely related to the fact that children with CF with lower SES to second-hand 
smoke to a greater degree (19, 22). The same study also examined gene-environment 
interactions, and found that the CFTR gene which causes disease in CF, modifies the 
association between second-hand smoke and poor pulmonary outcomes in patients with CF. 
The delta F508 mutation on the CFTR gene causes complete loss of function, whereas some 
non-delta F508 mutations allow partial function of the CFTR gene. The pulmonary function of 
patients carrying at least one non-Delta F508 mutation was more greatly affected by second-
hand smoke exposure than the delta F508 homozygous patients. Further studies involving 
patients who both homozygous and heterozygous for the delta F508 mutation are needed to 
explore the negative effects of second-hand smoke on pulmonary function of patients with 
CF (22).  
 




It is a widely-accepted fact that adequate nutrition in patients with CF is crucial for their 
quality of life and ultimately impacts on their survival. The relationship between malnutrition 
and progression of lung disease has been demonstrated in multiple studies from developed 
countries (23). Malnutrition in patients with CF is multifactorial, and results from poor 
absorption due to pancreatic insufficiency, anorexia and chronic suppurative lung disease 
which increases energy requirements. Besides negatively impacting lung growth, malnutrition 
can also reduce muscle mass which results in reduced force of contraction of the diaphragm 
and other respiratory muscles and impaired lung function. This, together with impaired 
immunity and antioxidant deficit due to malnutrition, makes malnourished children with CF 
particularly vulnerable to infection and pulmonary inflammation (23, 24).  
The most accepted measurement to assess the nutritional status of patients with CF is the 
body mass index (BMI). A cross-sectional study performed in a CF centre in Brazil involving 
patients from 6 to 18 years showed that BMI on the 50th percentile or more was associated 
with more desirable FEV1 of greater than or equal to 80 % (23). Pedreira et al also 
demonstrated a significant correlation between BMI Z score and FEV1, as well as muscle mass 
and FEV 1 (25). Chaves et al (2009) also showed an association between BMI and pulmonary 
function, but cautioned that BMI does not describe body composition and should not be used 
alone to assess the nutritional status of patients with CF. In CF there is a disproportionate loss 
of lean muscle mass due to the body favouring protein degradation rather than protein 
synthesis to meet its energy requirements, thus reduced pulmonary function can result from 
malnutrition due to a change in body composition (26).  Although body wasting has clearly 
been shown to be an independent predictor of mortality in patients with CF , there is a paucity 
of evidence regarding the association between stunting and mortality in CF patients. Previous 
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studies suggesting that stunting was related to mortality did not adjust for confounding 
variables, however a case-control study by Vieni et al (2012) specifically adjusted statistical 
analysis for age, gender, genotype, pancreatic status and CF-related diabetes, BMI, 
Pseudomonas or Burkholderia cepacia colonisation and FEV1. This was the first study to show 
that stunting is an independent risk factor for mortality in CF patients, and that nutritional 
interventions for stunting alone, is justified (27). 
Albumin is a powerful antioxidant necessary to maintain pulmonary glutathione levels. It has 
been found that some patients with CF have oxidatively modified albumin in their sputum, 
which may cause the albumin to lose its antioxidant properties (23). Albumin level has been 
related to the severity of pulmonary disease and prognosis in patients with CF (28). In a cross-
sectional study in Brazil by Forte et al (2012), patients with FEV1 <80% had significantly 
different albumin levels, despite the albumin being within normal range (28). The relationship 
between low plasma albumin and greater morbidity and mortality in CF patients has been 
described. A study that examined a model used to predict life expectancy in patients with CF 
showed that plasma albumin levels could predict survival (23).  
 
INFECTIONS: 
Airway infection and the ensuing airway inflammation is responsible for up to 95% of 
morbidity and mortality in patients with CF. Both impaired mucociliary clearance and viscous 
airway secretions are factors which promote respiratory tract infections in patients with CF. 
These factors are ultimately the result of an absent or dysfunctional CFTR protein due to 
mutations in the CFTR gene (29).  
 




-Aspergillus fumigatus  
Filamentous fungi are frequently cultured from respiratory secretions in patients with CF, but 
their clinical significance remains uncertain (30). The most common fungal microorganism 
isolated from CF airways is Aspergillus fumigatus (AF), with a prevalence reported between 
16 and 58% (31-34). In a study by Reece et al, AF colonisation was found to be most prevalent 
in in pre-adolescents and adolescents. There is currently no consensus on the treatment of 
asymptomatic AF colonisation, in light of the fact that AF does not usually cause invasive 
infections in patients with CF. Allergic bronchopulmonary aspergillosis, however, which may 
result from a hypersensitivity reaction to AF, has been proven to have a severe adverse 
influence on airway inflammation. The effect of AF on disease progression in patients with CF 
has been studied, but it remains unclear (29). An 8-year retrospective cohort study by 
Saunders et al (2016) concluded that AF colonization may be associated with worse 
pulmonary function (30). In a retrospective cohort study by de Vrankrijker et al (2011), it was 
noted that although AF colonization was more commonly found in patients with more 
significant lung disease, AF was not independently associated with worse lung function or a 
more rapid decline in lung function (35). A bidirectional relationship between AF colonisation 
and poor lung function has been postulated, and was demonstrated in the results of case 
control study by Noni et al (2015), in which the investigators concluded that whilst a lower 
FEV1 baseline is a risk factor for AF chronic colonization, AF itself may also cause a more rapid 
worsening of pulmonary function (36). Other studies, including a retrospective study by Reece 
et al conducted on data obtained from the Cystic Fibrosis Registry of Ireland (2013), have 
shown no causal relationship between AF colonization and worsening pulmonary function 
(29). This finding may be due to correction for confounders and baseline pulmonary function.  




The most common bacterial organism in CF is Pseudomonas aeruginosa. In patients with CF, 
P. aeruginosa colonization is usually intermittent early on, however, if re-colonisation occurs, 
with failure of eradication, patients may become persistently colonised with P. aeruginosa, 
after which pulmonary function declines and mortality increases (29). A systematic review by 
Harun et al noted a significant association between chronic infection with P. aeruginosa and 
CF pulmonary disease progression in all studies that examined this outcome measure (1), 
however evidence to the contrary exists, for example a study by Amin et al found that P. 
aeruginosa was not associated with a decline in lung function (37). Kerem et al (2014) found 
the likelihood of severe lung disease was 2.4 times higher in patients with CF and chronic 
Pseudomonas infection (14). A South African Study by Pentz et al conducted at Steve Biko 
Academic Hospital in Pretoria (2014) also demonstrated that patients with CF with P. 
aeruginosa colonisation had a decline in pulmonary function (8). Similarly, this study showed 
that patients with CF who were colonised by P. aeruginosa had a greater rate of change in FEF 
25-75 than those who were not colonised (8). Patients develop antibodies to Pseudomonas 
when they are colonised with the organism, and it is thought that this immune response plays 
a role in the lung damage in patients with CF. In a study by Winnie and Cowan (1991), patients 
with CF with chronic Pseudomonas infection had higher antibody levels and worse pulmonary 
function (38).  
P. aeruginosa infection may be further subclassified into mucoid and non-mucoid types, the 
former being associated with more rapid decline in pulmonary function than non-mucoid P. 
aeruginosa infection. (1). In a study by Sanders et al, investigators found no association 
between FEV1 and P. aeruginosa infection in general, but there was a significant association 
between FEV1 and mucoid Pseudomonas (9). Besides the decline in lung function, P. 
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aeruginosa colonisation also severely impairs growth and the quality of life of patients with 
CF (8).  
Methicillin-resistant Staphylococcus aureus (MRSA):  
 
First identified in 1960, Methicillin-Resistant Staphylococcus aureus (MRSA) general infection 
is increasing in the paediatric population, as is its isolation in the sputum of paediatric patients 
with CF (39). Despite this, there are still few studies assessing the impact of MRSA on 
pulmonary function in patients with CF. Results of studies are also conflicting, with some 
showing that MRSA does not impact on pulmonary function, and others indicating that MRSA 
is associated with deterioration of, and overall poorer, pulmonary function(40). Ren at al 
(2007) conducted a cross sectional study using data from the Epidemiologic Study of Cystic 
Fibrosis. They showed that patients with CF and MRSA infection had a lower mean FEV1 % 
predicted than those with methicillin-sensitive Staphylococcus aureus (MSSA) (41). MRSA 
infection is known to be associated with more severe lung disease in patients with CF, as well 
as a generally lower FEV1. Dasenbrook et al conducted a large 10-year Cohort study (2008) 
using the CF Foundation patient registry in North America which was able to perform an in-
depth analysis of the longitudinal effect of MRSA in CF. This study demonstrated that 
persistent infection with MRSA in patients with CF was associated with an increase in rate of 
pulmonary function decline of approximately 0,5 FEV1 % predicted per year, compared to 
those without MRSA. Importantly, the results of this study also suggested that, after adjusting 
for confounding factors, persistent MRSA infection was responsible for a decline in pulmonary 
function (40). 
Staphylococci possess toxins which damage cell membranes, as well as substances called 
invasins which assist with bacterial tissue invasion (40), however it is still unclear exactly how 
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MRSA may worsen pulmonary function in patients with CF. It has been noted that children 
with CF more commonly have community-aquired strains of MRSA which have increased 
virulence when compared to nosocomial strains (40). The exact mechanism by which MRSA 
causes a decline in lung function may be established by further studies examining MRSA 
molecular epidemiology and clinical outcomes (40).  
 
1.3 STUDY RATIONALE: 
The purpose of this research is to outline the changes in lung function that occur over time in 
a paediatric and adolescent population with CF, attending the Red Cross War Memorial 
Children’s Hospital (RCWMCH) CF Clinic (Cape Town, South Africa), and to investigate the 
factors that affect lung function decline. By doing so we hope to identify high risk patients in 
whom more aggressive treatment and modification of risk factors would be beneficial. This 
could also form the basis of further research, the results of which may positively impact on 
future management of children and adolescents attending the CF clinic at RCWMCH. 
 
1.4 ETHICAL CONSIDERATIONS: 
The study described in chapter 2 was a retrospective review of data retrospective review of 
data routinely collected as part of the approved CF  
database (HREC 119/2011). Informed consent to record patient data in the registry was 
previously obtained from the parents/guardians of all potential participants.  
 
The study population is a recognised vulnerable group, being children with a severe, chronic 
disease; however, considering the descriptive, non-interventional nature of the study and the 
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use of anonymised data, this study was deemed to constitute minimal risk of research-related 
harm to the minor participants. The only foreseeable harm would arise from breach of 
confidentiality, and the following measure are in place to minimise this risk:  
 
i. Patient identifiers were removed and replaced by a code.  
ii. No potentially identifying or identifiable information will appear in any output arising 
from this research.  
iii. Hard copies of data are stored in a locked filing cupboard. 
iv. Electronic copies of data are saved in password protected files accessible  
only to the researchers. 
 
 
Although the study held no potential benefit to participants, the generalizable knowledge 
which will contribute to better understanding and future management of children with CF in 
South Africa.  
 
The study adhered to the provisions of the Declaration of Helsinki (2013) (42) and the 2015 
South African National Department of Health’s “Ethics in Health Research: Principles, 
Processes and Structures” (2nd Edition) (43). The study was approved by the University of Cape 
Town’s Faculty of Health Sciences Human Research Ethics Committee (HREC) (Rec Ref: 
830/2017). 
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Objectives: Cystic fibrosis (CF) is one of the commonest inherited disorders in South Africa, 
affecting all population groups. Progressive pulmonary disease with declining forced expiratory 
volume in one second (FEV1) is the main predictor of morbidity and mortality in individuals with 
CF. This study aimed to describe the change in lung function, nutritional status and mortality of 
children and adolescents with CF, attending the Red Cross War Memorial Children’s Hospital 
(RCWMCH) CF Clinic and to identify factors associated with poor pulmonary function outcomes 
and mortality. 
 
Methods: A retrospective study was conducted of the clinical records and annual pulmonary 
function tests, with matched body mass index (BMI), of children between 5 and 18 completed 
years of age attending the RCWMCH CF clinic in Cape Town, South Africa, between January 2007 
and December 2016.  
 
Results: A total of 143 study participants (51.4% male; median age at diagnosis 5.5 months) were 
included. Population mean FEV1 and body mass index (BMI) Z scores improved from -2.5  1.70 
to -1.9  1.70 (p = 0.1) and from -0.7  1.2 to -0.4  1.2 (p = 0.3) respectively from 2007 to 2016. 
FEV1 Z score declined by an average of 0.17 per year of age and this was mirrored by an average 
decline in BMI Z scores of 0.07 for each year of advancing age. FEV1 decline was greater in 
patients who died compared to those who survived (p = 0.03). Of the factors postulated to 
influence lung function decline, there was no significant correlation between FEV1 at any age and 
age of diagnosis, sex, ethnicity, genotype, geographical location, pancreatic status, or Methicillin-
resistant S. aureus or Aspergillus spp. infection. Participants who were ever infected or colonised 
with P. Aeruginosa had consistently lower FEV1, however this difference only became significant 
at certain ages. On multiple stepwise regression analysis, only FEV1 at age 6 was found to be a 
significant independent predictor of mortality (adjusted odds ratio (95% CI) 0.5 (0.3 – 0.8); p = 
0.005).  
 
Conclusion: Pulmonary function of children with cystic fibrosis improved non-significantly over 
the 10-year study period. FEV1 at age 6 was identified as an independent predictor for CF-related 
mortality. Early diagnosis and measurement of pulmonary function in young children with CF is 











Cystic fibrosis (CF) is a genetic disorder of autosomal recessive inheritance (1) which is one of 
the commonest inherited disorders in South Africa, affecting all population groups (2). It is 
caused by a mutation in the gene encoding for the cystic fibrosis transmembrane conductance 
regulator (CFTR) protein (1), resulting in chronic progressive multisystem disease (3). The 
pathological basis of CF lung disease is chronic endobronchial infection and inflammation 
which gradually causes airway obstruction and damage ultimately resulting in irreversible 
obstructive lung disease and respiratory failure (4, 5).  Lung disease is the strongest predictor 
of morbidity and mortality in patients with CF (6). An objective way of measuring the  
progression of CF lung disease  is using pulmonary function tests (PFT) (7).  Forced expiratory 
volume in 1 second (FEV1) is the most widely used measurement to guide clinical 
management of patients with CF as it has been shown to be a predictor of hospitalisation and 
is strongly associated with mortality (3, 7).  
 
Numerous factors associated with FEV1 decline have been identified through studies 
conducted in high income countries (8). These factors can be divided into non-modifiable and 
modifiable groups.  Non-modifiable factors include sex, genotype, and pancreatic sufficiency 
(1). The relationship between sex and pulmonary function decline is still unclear, with 
international studies demonstrating that female sex is associated with steeper FEV1 decline 
(1, 9, 10), however in the only South African study examining the rate of pulmonary function 
decline in children with CF, no gender-related difference in FEV1 decline could be 
demonstrated (7). A definitive genotype-phenotype correlation in patients with CF is difficult, 
because the presentation, clinical evolution and prognosis for these patients is varied (11). 





Pancreatic insufficiency has been associated with a steeper decline in FEV1 (1, 10, 12), 
however there is a paucity of South African studies examining this relationship.  
 
Modifiable factors influencing FEV1 include age at CF diagnosis, socioeconomic status, 
nutrition and infections. The advent of newborn screening in high income countries has 
contributed to earlier diagnosis and improved outcomes (13-15), (16, 17). In a SA study by 
Morrow et al, children diagnosed with CF after 5 years of age had worse pulmonary function 
compared to those diagnosed before 5 years age (7). There is thus compelling evidence that 
early diagnosis and optimal timeous management is essential to improve pulmonary function 
outcomes and survival in patients with CF. 
 
South Africa is a low-middle income country (LMIC) with high unemployment and extreme 
wealth and socioeconomic inequality. Connections have been drawn between poorer socio-
economic status and worse clinical outcomes in patients with CF (18), both in terms of lung 
function and a higher mortality rate (19). This is likely due to the fact that low socioeconomic 
status is associated with poorer  nutrition (19), greater exposure to second-hand smoke (19, 
20), and poorer adherence to both medical and airway clearance therapies (21).   
 
Airway infection and the ensuing inflammation is responsible of up to 95% of morbidity and 
mortality in patients with CF (21) and Pseudomonas aeruginosa (P.aeruginosa) is the most 
common bacterial organism in CF (22). Persistent colonisation by P. aeruginosa after failure 
of eradication leads to a faster decline in pulmonary function and an increase in mortality, 
including in SA (7) (22) (23).  





Studies examining factors associated with pulmonary function decline in LMICs are lacking.  
 
This study aimed to describe the change in lung function and mortality of children and 
adolescents with CF, attending the RCWMCH CF Clinic (Cape Town, South Africa) over the 10-
year period between January 2007 and December 2016. We further aimed to identify factors 
associated with poor pulmonary function outcomes in which more aggressive treatment and 
modification of risk factors may be beneficial. 
METHODS 
Study design and setting 
 
A retrospective study of the clinical records and pulmonary function tests of children between 
5 and 18 completed years of age attending the Red Cross War Memorial Children’s Hospital 
(RCWMCH) CF clinic between January 2007 and December 2016 was conducted. This study 
was approved by the University of Cape Town Human Research Ethics Committee (HREC Ref 
830/2017).  
RCWMCH is a tertiary paediatric referral hospital situated in the Western Cape province of 
South Africa. Multidisciplinary CF care, according to SA guidelines (24), and access to essential 
CF medications is provided either free for poor families or through health care insurance in 
families who can afford this.   Newborn screening for CF is not performed in South Africa and 
CF diagnosis is predominantly symptom-based. A significant number of patients at RCWMCH 
come from marginalised communities with poor socio-economic circumstances.  
 





Study participant selection 
Eligible participants were identified by reviewing the RCWMH CF clinic database and medical 
records of patients attending the CF clinic between January 2007 and December 2016. Only 
children between 5 and 18 completed years of age with a confirmed diagnosis of CF were 
included. The diagnosis of CF in participants was based SA consensus guidelines (24) which 
includes either two positive sweat tests (sweat chloride > 60mmol/L) and clinical features 
compatible with CF disease and/or identification of two pathogenic CFTR variants. Children 
less than 5 years of age were excluded as young children are not reliably able to perform 
spirometry. 
  
Clinical data and outcome measures 
Participants were only included if they had performed at least two pulmonary function tests, 
one year apart, during the period of January 2007 to December 2016. The pre-bronchodilator 
PFT, weight and height measured on or closest to the participant’s birthday was selected. If 
participants were unwell on this clinic visit, the next closest PFT conducted during a period of 
wellness, was utilised.  
Data extracted from the CF clinic database and medical records included: date of birth, 
gender, CF genotype, age of CF diagnosis, mortality and age of death, ethnicity, presence of 
P.aeruginosa, Methicillin-resistant Staphylococcus Aureus (MRSA), aspergillus infection, age 
of first P.aeruginosa infection and P.aeruginosa colonisation, body mass index (BMI) at the 
time of PFT measurement, pancreatic sufficiency, and geographical location of habitation.  
The following baseline PFT parameters were used for analysis: FEV1, Forced vital capacity 
(FVC, and average expiratory flow between 25 and 75% of FVC (FEF25-75/ MEF). The 
percentage predicted for age, gender, height and ethnic group was used for analysis, along 





with the all-age (3-95 years), multi-ethnic Global Lung Function Initiative (GLI) spirometry 
equations (Z-scores), according to norm-referenced data (25). 
Statistical analysis 
For descriptive statistics, data were tested for normality using the Shapiro-Wilks W test, and 
presented as means (standard deviation) or median (interquartile range) and n (%), according 
to distribution. Changes in population characteristics and annual PFT between 2007 and 2016 
were analysed using repeated measures ANOVA with post-hoc-t-tests for dependant 
variables/Wilcoxin matched-pairs tests and t-tests for independent variables/Mann-Whitney 
U and chi-square tests, according to data distribution. Multivariate regression analyses will be 
used to assess the main effects on the changes in PFT variables. Longitudinal data was 
analysed using mixed model regression analysis (10).Repeated measures between- and within 
group ANOVAs will be conducted to determine changes in PFT with advancing age (from 5-18 
years of age); and to determine the main effect variables (e.g. pancreatic sufficiency, 
ethnicity/genotype, infection status, and sex). Mortality (number of deaths) per annum will 
be recorded and plotted. Statistica version 13 (StatSoft, USA) was used for data analysis and 
a significant level of p<0.05 will be chosen, with Bonferonni correction where appropriate. 
 
RESULTS 
A total of 143 study participants were identified from the RCWMCH CF Clinic database. Of 
these, 107 participants (51, 4% male) were included in this study, the majority (55%) 
homozygous for the p.Phe508del mutation and pancreatic insufficient (79 %)  (Figure 1  table 
1). Of these 107 participants, one was lost to follow up, 14 (15%) patients died during the 
study period and 35 (37,5%) patients were transferred to other facilities or healthcare 
providers for ongoing medical care.  
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Total study participants 
n = 143 
Included 
n = 107 Excluded (N =36)   
• folders could not be 
located (n=6) 
• patients died before  5 
years age  (n=20) 
• patients lost to follow up 
(n=6) 
• patients managed almost 
exclusively at other 
facilities (n=3) 
• study participant later 
found not to have CF (n=1) 
Lost to follow up 
n = 1 
Died during study 
period 
n = 14 
Transferred to 
other facility 
n = 35 
 





Table 1: Study participant characteristics 
Age at diagnosis (months) 5,5 (2,00 – 26,00) 
Male gender  55 (51,4) 
Sweat chloride (mmol/l) 104 (90 – 113) 
Ethnicity  
White 62 (57,9) 
Black African 6 (5,6) 
Mixed ancestry 38 (35,5) 
Asian 1 (0,9) 
Genotype category  
p.Phe508del homozygous 55 (51,4) 
p.Phe508del heterozygous 29 (27,1) 
Other 18 (16,8) 
Unknown 5 (4,7) 
Geographical area of residence  
Greater Cape Town Metropole (<100km)   67 (62,6) 
Western Cape (>100km from Cape Town) 24 (22,4) 
Other 16 (15) 
Pulmonary infections  
Age at first PA years (n=80)  7,50 (3,00 – 13,00) 
Age at PA colonisation  (mean  SD) years (n=29) 10,2 4,85 
Ever Aspergillus fumigatus. 43 (40,2) 
MRSA 10 (9,3) 
Ever non-tuberculous mycobacteria 9 (8,4) 
Outcome  
Died during study period 14 (13,1) 
Lost to followup 1 (0,9) 
Transferred 35 (32,7) 
Continuous data are presented as median (IQR), unless otherwise stated. Categorical data are n (%); 
MRSA: Methicillin Resistant Staphylococcus Aureus; PA: Pseudomonas aeruginosa  





Change in population lung function and average annual rates of change: 
There was an overall improvement in population lung function and BMI during the study 
period, as defined by FEV1, FVC and FEF 25-75, however this change was not significant. (Table 
2). 
 
Table 2: Population change in lung function and BMI Z scores from 2007 to 2016.  
 2007 2016 p 
FEV1 Z score -2,48  1,70 -1,89  1,69 0,1 
FVC Z score -1,95  1,62 -1,47 1,80 0,2 
FEF 25-75 Z score -2,43  1,84 -1,91  1,41 0,1 
BMI Z score -0,74  1,22 -0,43  1,19 0,3 
Data are mean  SD. FEV1: forced expiratory volume in one second; FVC: forced vital capacity; 
FEF25-75: Forced expiratory flow between 25%-75% of the forced vital capacity; BMI: body mass 
index. 
 
FEV1, FVC and FEF 25-75 Z scores all declined steadily with advancing age in our study 
population, with an estimated average decline of 0,17; 0,12; and 0,19 respectively per year of 
age (Figure 2). The decline in pulmonary function with age was mirrored by an estimated 
decline in BMI Z scores of 0,07 for each year of advancing age (Figure 2). 






Figure 2: Annual rates of decline in pulmonary function and body mass index (BMI). 
 
FEV1 was generally lower in patients who survived compared to those who died (current effect Anova 
F(13,91)=1,99;  p = 0.03), however the mean annual rate of FEV1 decline  was similar: 0.16 ± 0.61 in 
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Figure 3: Mean change in FEV1 for survivors compared to those who died (p = 0.03) 
 
Determinants of lung function:  
The median age at diagnosis was 5.5 months (IQR 2.00-26.00). There was no significant 
correlation between age of diagnosis and FEV1 Z scores at any age. There were no statistically 
significant differences between FEV1 between male and female participants at any given age; 
and the pattern of change was also similar over time (Anova current effect F (13,91) = 1,39; 
p=0,2). Similarly, there were no significant effects of ethnicity, genotype, geographical 
location, pancreatic status, or MRSA or Aspergillus infection on FEV1 at any age (p>0.05). 
Whilst FEV1 in patients that had ever been infected with P. aeruginosa was consistently lower 
than FEV1 in patients who had never been infected with P. aeruginosa, the difference only 
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patients who were colonised with P. aeruginosa had consistently lower FEV1 values than 
those who were not colonised, however this difference was only significant at age 6 (p=0,03), 
14 (p=0,04) and 19 (p=0,02) years of age. There was a significant correlation between BMI 
and FEV1 Z scores (R=0,92; p<0,01) (Figure 4). Age at first P. aeruginosa infection was 
associated with poor FEV1 at age 6; there were no other potential predictors of poor FEV1 at 
age 6 on bivariate analysis (Table 3). 
 
 
Figure 4: Correlation between BMI and FEV1 Z scores (p< 0,01) 
 
Only FEV1 at age 6 and P. aeruginosa colonisation were significant predictors of mortality on 
bivariate analysis (Table 4). On entering these variables into a stepwise multiple logistic 





regression, only FEV1 at age 6 remained a significant independent predictor of mortality in 
children with CF (adjusted odds ratio (95% confidence interval) 0,5 (0,31 – 0,81); p = 0,005). 
 







Male sex 9 (64,3) 46 (49,5) 0,5 
PI 12 (85,7) 73 (78,5) 0,8 
Age at diagnosis 6 (3 – 37) 5 (1-24) 0,5 
Ever PA 13 (92,9) 68 (73,1) 0,2 
PA colonised 8 (57,1) 21 (22,6) 0,009 
Age at PA 6 (3-8) 8 (2-13) 0,6 
Age (y) PA colonised 9 (4 – 12,5) 11 (8 – 15) 0,3 
FEV1 Z score age 6 (mean   SD) -2,65  2,54 -0,88  1,37 0,003 
BMI Z score age 6 (mean  SD) -0,66  1,20 -0,27  1,90 0,5 
Ever MRSA 1 (7,1) 9 (9,7) 0,9 
GENOTYPE    
p.Phe508del homozygous 7 (50) 48 (51,6) 0,7 
p.Phe508del heterozygous 5 (35,7) 24 (25,8) 
Other 2 (14,3) 16 (17,2) 
Unknown 0 (0) 5 (5,4) 
Ethnicity    
Mixed ancestry 4 (28,6) 34 (36,6) 0,9 
White 9 (64,3) 53 (57,0) 
Asian 0 (0) 1 (1,1) 
Black African 1 (7,1) 5 (5,4) 
PI: Pancreatic Insufficient; PA: Pseudomonas; MRSA: Methicillin-resistant Staphylococcus aureus 
 
DISCUSSION: 
This study investigated the change in lung function and mortality of South African children 
and adolescents with CF over a 10-year period and examined the modifiable and non-
modifiable predictors of lung function decline in these patients. There was a non-significant 
improvement in the lung function of our study population over the 10-year study period,  
similar to the improvement in lung function reported previously by Morrow et al from the 
same centre  during the 8-year period between January 1999 to December 2006 (2). This 





ongoing improvement in population lung function of South African patients with CF is 
encouraging and reflects continued improvement in holistic CF management at our centre.  
 
With advancing age of our study population, we showed that PF declined accordingly over 
time. Importantly, the rate of PF decline was not significantly influenced by factors such as 
age of diagnosis, genotype, ethnicity, gender or infections. However, a lower FEV1 from age 
6 years was associated with P.aeruginosa infection and increased mortality. This important 
observation, noted too in international CF registry data (26), implies that early life 
determinants of lung function play a critical role in predicting CF survival. Earlier acquisition 
of P. aeruginosa was the only predictor of poorer FEV1 at age 6 in our cohort, although 
causality cannot be determined on the basis of this study design. P. aeruginosa infection was 
not statistically associated with mortality in our study which is in contrast to international 
experience, likely due to small sample size and other unmeasured modifiable factors (27-29). 
Clinical interventions that focus on mitigating factors that influence early lung function and 
reduce mortality are needed.  More sensitive tools to measure and monitor lung function in 
very young children must enter the routine clinical practice realm in order to identity at risk 
infants and children and address these modifiable factors. 
 
Studies from high income countries have demonstrated an association between malnutrition 
and progression of lung disease (30). Similarly, our study showed a significant correlation 
between BMI and FEV1, and demonstrated that as pulmonary function declined with age, so 
too did BMI. Malnutrition in patients with CF may partly be caused by poor absorption due to 
pancreatic insufficiency (30, 31). Studies by Corey et al and Harun et al showed that pancreatic 





insufficiency was associated with a steeper decline in FEV1 (1, 10). Our study showed no 
significant effects of pancreatic status on FEV1 at any age, which may reflect earlier detection 
and improved management of pancreatic insufficiency in our study population, thereby 
mitigating accelerated BMI decline and also preserving FEV1. The relationship between 
nutrition and pulmonary function in CF is a complex, multifactorial one. Poor absorption due 
to pancreatic insufficiency, anorexia, chronic suppurative lung disease, chronic inflammation 
with increased energy requirements and increased basal metabolic rate all contribute to 
malnutrition (30-32) (33). Malnutrition also reduces muscle mass resulting in reduced force 
of contraction of respiratory muscles and impaired lung function, making children with CF 
particularly vulnerable to infection and pulmonary inflammation (30-32) (33).  One may thus 
deduce that, because of this multifactorial association between nutrition and FEV1, and the 
fact that FEV1 is strongly associated with mortality in patients with CF (3, 7), malnutrition may 
ultimately impact on their survival (30).  
 
The median age of diagnosis of CF in our study population was 5.5 months and we did not 
show a correlation between age of diagnosis and FEV1 scores at any age.  This is surprising 
considering evidence of the positive impact of early diagnosis and NBS on CF nutrition, PF and 
other CF-related outcomes (34). Results of international studies have been inconsistent, with 
some studies indicating no difference in lung function of children with CF diagnosed early 
versus those diagnosed later (13-15), and other studies demonstrating better lung function in 
children with CF who were diagnosed at an early age (16, 17). In a SA study by Morrow et al 
(7), children with CF diagnosed before 1 year of age had less severe lung disease than those 
diagnosed after 5 years of age. An explanation for this contrasting observation may be that 





the majority of children in our more recent cohort were diagnosed relatively young thus 
eliminating any effect of delayed diagnosis age on pulmonary function. More research is 
needed to investigate the cost-benefit value of implementing CF NBS programmes in LMICs 
such as South Africa.  
 
This study was limited by small sample size and that this was a single centre study. Despite 
including patients from both urbanised and more rural areas, it was conducted in the Western 
Cape which is one of the more developed provinces in South Africa. It involved study 
participants attending RCWMCH CF clinic, an institution which is relatively well resourced, 
compared to many other healthcare facilities in South Africa. Therefore, results may not be 
completely representative of South African children with CF.  Another limitation is we were 
unable to measure or document socioeconomic modifiable factors determining pulmonary 
function and survival in this cohort.  Factors such as household cigarette smoke or biomass 
fuel exposure, caregiver education, food security, household income and adherence to 
treatments were not accurately recorded in the medical records as these are difficult to 
quantify in a consistent and reliable way.  We excluded 20 children who died before they were 
old enough to have PF testing. This highlights the importance and likelihood of other early life 
factors in determining CF survival in SA that were not examined in this study. 
 
In conclusion, we demonstrated a positive trend of improving PF in our CF study population 
over the 10-year study period. However, rate of PF decline over time correlated with declining 
BMI but was similar regardless of age of CF diagnosis, genotype, gender or race.  FEV1 at age 
6 was the strongest predictor of mortality, and there was a weak association of lower FEV 1  





in those infected and colonised by P. aeruginosa .Identifying modifiable factors in infancy and 
early life that affect CF outcomes and improved tools to measure and monitor pulmonary 
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